Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Microsoft Launches Automatic Energy-Saving Mode For Select XBox Users Moving Closer To Environmental Goals – $MSFT $DIA $ATOS $INM

By John F. Heerdink, Jr.

As per reports, Microsoft Corp. (MSFT) is working on an energy-saving update to its Xbox gaming consoles aiming to meet a 2030 deadline for its environmental goals. Starting Xbox Insiders, a subset of users will be automatically switched to a newly introduced energy-saving Shutdown option. When left idle consoles will use less power than in Sleep mode, which enables users to wake up devices and start gameplay more quickly. The Insider program is a small group of gamers that get an early look at features and content in development.

As more people get involved and gaming hardware uses more power, gaming has a substantial carbon footprint that is on track to increase.

“This one-time update to the power settings will reduce power consumption while the console is off, and will not affect performance, gameplay, or the console’s ability to receive overnight updates to the system, games, or apps. Cuts power use by up to 20X when it’s off compared to Sleep” and every two consoles that switch to the energy-saving mode will “save the carbon equivalent of one tree planted and grown for a decade,” informed Blaine Hauglie, technical program manager.

Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses supports, and sells computer software, consumer electronics, personal computers, and related services. To learn more about Microsoft (MSFT) and to track their progress please visit the Vista Partners Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

Consider visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury.


On January 10, InMed Pharmaceuticals Inc. (Nasdaq: INM) issued a press release, which outlined their key accomplishments from 2022 and provided business update and catalysts for 2023 including the following interesting milestones for 2023:

  • Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023
  • Progress preclinical research in glaucoma in preparation for human trials
  • Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
“Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how. Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed was able to advance its programs and achieve a number of key milestones. As we move forward into 2023, we are very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters,” stated Eric A. Adams, InMed President and CEO.


INM-755 in Epidermolysis Bullosa

  • Activated 11 clinical trial sites in seven countries for the Phase 2 study

  • Expanded from adult subjects to include adolescents following independent review of early safety data

  • Progressed clinical trial with enrollment and treatment of 15 patients, with the 16th patient enrolled for treatment in early January 2023

To review the balance of the this report please follow us by clicking here!

(Read Original Story: Microsoft Rolls Out Automatic Energy-Saving Mode for Select XBox Users in Bloomberg)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us